UTI Program (with GSK)
Treatment & Prevention of Recurrent Urinary Tract Infections
Phase 1Active
Key Facts
Indication
Treatment & Prevention of Recurrent Urinary Tract Infections
Phase
Phase 1
Status
Active
Company
About Fimbrion Therapeutics
Fimbrion Therapeutics is pioneering an antibiotic-sparing approach to combat bacterial infections through its antivirulence platform. The company has established a significant partnership with GSK, which has advanced a UTI candidate into Phase I clinical trials and secured CARB-X funding for its development. With strong academic roots, NIH SBIR grant support, and a focus on high-need areas like recurrent UTIs and tuberculosis, Fimbrion is positioned as an innovator in addressing the global antimicrobial resistance crisis.
View full company profile